POLYETHYLENE GLYCOL 3350
drugOn this page
Also known as Carbowax 3350GlycolaxLipo polyglycol 3350Lipoxol 3350 medLumulse peg 3350Macrogol 3350MiralaxNER-1006NER1006Polyglykol 3350Protachem 75
Summary
Polyethylene Glycol 3350 (CHEMBL1201479) is an approved small molecule; indicated across 11 conditions including constipation disorder and diabetes mellitus.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 11 conditions
- Clinical trials: 40
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201479 |
| Name | POLYETHYLENE GLYCOL 3350 |
| Type | Small molecule |
| Max phase | 4 |
Also known as: Carbowax 3350, Glycolax, Lipo polyglycol 3350, Lipoxol 3350 med, Lumulse peg 3350, Macrogol 3350, Miralax, NER-1006, NER1006, Polyethylene glycol 3350, Polyglykol 3350, Protachem 75
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
11 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| constipation disorder | 4 | MONDO:0002203 | HP:0002019 |
| diabetes mellitus | 3 | MONDO:0005015 | EFO:0000400 |
| colorectal carcinoma | 3 | MONDO:0024331 | EFO:1001951 |
| hepatitis C virus infection | 3 | MONDO:0005231 | EFO:0003047 |
| chronic hepatitis C virus infection | 3 | MONDO:0005354 | EFO:0004220 |
| colonic neoplasm | 3 | MONDO:0005401 | MONDO:0021063 |
| colorectal neoplasm | 3 | MONDO:0005335 | MONDO:0005575 |
| Crohn disease | 2 | MONDO:0005011 | EFO:0000384 |
| Clostridium infectious disease | 2 | MONDO:0024388 | EFO:1000874 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 40.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 17 |
| Not specified | 9 |
| PHASE2 | 5 |
| PHASE3 | 3 |
| PHASE1/PHASE2 | 3 |
| PHASE2/PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05805436 | PHASE4 | RECRUITING | Preop Laxatives in Robotic Urologic Surgery |
| NCT06825260 | PHASE4 | RECRUITING | PEG3350 vs Senna After Urogyn Surgery |
| NCT00171522 | PHASE4 | COMPLETED | Preference of Tegaserod vs. PEG 3350 in Patients With Constipation |
| NCT00319670 | PHASE4 | COMPLETED | A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children |
| NCT00770432 | PHASE4 | COMPLETED | Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(P08216) |
| NCT01063049 | PHASE4 | COMPLETED | Gatorade/Miralax With or Without Bisacodyl Versus NuLytely for Colonoscopy Preparation |
| NCT01719653 | PHASE4 | COMPLETED | A Comparison of 5 Low Volume Bowel Preparations |
| NCT01773096 | PHASE4 | COMPLETED | Methylnaltrexone Use for Opioid-induced Postoperative Constipation |
| NCT02336906 | PHASE4 | WITHDRAWN | Urotherapy vs. Urotherapy With Constipation Treatment for Children With Lower Urinary Tract Dysfunction |
| NCT02337413 | PHASE4 | WITHDRAWN | Urotherapy vs. Urotherapy With Constipation Treatment for Nocturnal Enuresis |
| NCT03060512 | PHASE4 | COMPLETED | To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation |
| NCT03800745 | PHASE4 | COMPLETED | Reduction of Postoperative Gastrointestinal Dysmotility Following Total Laparoscopic Hysterectomy. |
| NCT04210427 | PHASE4 | COMPLETED | Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit |
| NCT04263896 | PHASE4 | COMPLETED | Bowel Function After Minimally Invasive Hysterectomy |
| NCT04585542 | PHASE4 | TERMINATED | Comparison of Potassium Binders in the ER |
| NCT04708366 | PHASE4 | UNKNOWN | Colon Cleansing Efficacy With 1L vs. 2L vs. 4L-PEG for Colonoscopy Among Inpatients |
| NCT06159777 | PHASE4 | COMPLETED | Pre-operative Polyethylene Glycol 3350 for Minimally Invasive Urogynecologic Surgery |
| NCT05897086 | PHASE2/PHASE3 | ENROLLING_BY_INVITATION | Polyethylene-glycol Assisted Nerve Repair in Phalloplasty |
| NCT02254486 | PHASE3 | COMPLETED | Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults |
| NCT02273141 | PHASE3 | COMPLETED | Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus a Sodium Picosulfate and Magnesium Salt Solution Using Day Before-Only Dosing Regimen in Adults. |
| NCT02273167 | PHASE3 | COMPLETED | Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus MOVIPREP® Using 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimen in Adults. |
| NCT04113382 | PHASE1/PHASE2 | RECRUITING | Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy |
| NCT04182633 | PHASE2 | ACTIVE_NOT_RECRUITING | MTT for Children With ASD Who Have Gastrointestinal Disorders |
| NCT06503978 | PHASE2 | ACTIVE_NOT_RECRUITING | Microbiota Transplant Therapy for Children With Both Autism Spectrum Disorder and Gastrointestinal Disorders |
| NCT01714466 | PHASE2 | COMPLETED | Pharmacodynamic and Clinical Evaluation of Dose and Taste-optimised Low Volume PEG-based Bowel Cleansing Solutions Using the Split-dosing Intake Regimen in Healthy Subjects and in Subjects Undergoing Screening Colonoscopy |
| NCT02272868 | PHASE1/PHASE2 | TERMINATED | Fecal Microbial Transplant in Pediatric Crohn’s Disease |
| NCT02765256 | PHASE2 | COMPLETED | Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn’s Disease |
| NCT03476317 | PHASE2 | COMPLETED | Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn’s Disease |
| NCT04270019 | PHASE1/PHASE2 | WITHDRAWN | Polyethylene Glycol to Improve Sensation Following Digital Nerve Laceration |
| NCT01834742 | PHASE1 | COMPLETED | Pharmacodynamic Evaluation of Stool Output Following Oral Administration of Various Low Volume PEG3350-based Gut Cleansing Solutions Using the Split Dose Intake in Healthy Subjects |
| NCT00765557 | EARLY_PHASE1 | COMPLETED | Randomized, Double-Blinded, Placebo-Controlled Trial of Laxatives for Children With Urge Syndrome |
| NCT05318365 | Not specified | RECRUITING | Bladder and Bowel Dysfunction in Children |
| NCT01028573 | Not specified | UNKNOWN | A Study Comparing PEG-3350 (Miralax) and Gatorade With PEG-ELS (Golytely) for Bowel Preparation Prior to Colonoscopy |
| NCT01518790 | Not specified | COMPLETED | Short Course, Single-dose PEG 3350 for Colonoscopy Prep in Children |
| NCT01566409 | Not specified | COMPLETED | Maintenance Treatment for Children With Constipation |
| NCT01691742 | Not specified | COMPLETED | MiraLAX Versus Placebo to Prevent Constipation Following Urogynecologic Surgery |
| NCT01923376 | Not specified | WITHDRAWN | Hepatic Encephalopathy: Lactulose or Polyethylene Glycol (H.E.L.P.) |
| NCT02102373 | Not specified | COMPLETED | Evaluation of Two Different Diet Regimen Prior to Colonoscopy in Children |
| NCT03247595 | Not specified | COMPLETED | Testing How Well Magnesium Citrate Capsules Work as Preparation for a Colonoscopy |
| NCT05726344 | Not specified | COMPLETED | Lactulose vs. Polyethylene Glycol as Bowel Preparation for Colonoscopy in Adults |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).